Azitra (NYSEAMERICAN:AZTR) Trading Down 5.1%

Azitra, Inc. (NYSEAMERICAN:AZTR) shares dropped 5.1% during mid-day trading on Thursday . The stock traded as low as $0.18 and last traded at $0.19. Approximately 607,320 shares were traded during mid-day trading, an increase of 18% from the average daily volume of 513,998 shares. The stock had previously closed at $0.20.

Azitra Stock Up 2.7 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.58 and a current ratio of 1.58.

Insider Buying and Selling

In related news, CEO Francisco D. Salva acquired 333,300 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was acquired at an average cost of $0.30 per share, with a total value of $99,990.00. Following the completion of the purchase, the chief executive officer now directly owns 338,300 shares in the company, valued at $101,490. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 399,200 shares of company stock valued at $115,476 over the last three months.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Warberg Asset Management LLC lifted its holdings in Azitra by 20.7% during the third quarter. Warberg Asset Management LLC now owns 35,000 shares of the company’s stock worth $52,000 after acquiring an additional 6,000 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Azitra in the second quarter valued at about $57,000. Finally, Knollwood Investment Advisory LLC bought a new stake in shares of Azitra in the third quarter valued at about $62,000. 11.16% of the stock is currently owned by institutional investors.

Azitra Company Profile

Azitra, Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S.